GLP-1 Science
GLP-1 and Smoking Cessation Research
Emerging research suggests semaglutide may reduce tobacco use, an unexpected finding still being actively studied. Here...
The last decade of weight loss medicine follows one clear pattern. Every time researchers added another hormone receptor to the target list, weight loss went up.
One receptor produced roughly 15 percent. Two produced roughly 21 percent. Three produced roughly 24 percent.
Understanding what each receptor actually does explains why, and it also explains why this cannot continue indefinitely.
The word agonist
An agonist is a substance that activates a receptor, producing the same response the body's natural signal would.
These drugs are copies of your own gut hormones, engineered to survive far longer. Natural GLP-1 lasts about two minutes. Semaglutide lasts about a week.
A dual agonist activates two receptor types. A triple agonist activates three.
What each receptor does
GLP-1 (glucagon-like peptide-1) is released by your gut after eating. It slows stomach emptying, signals fullness to your brain, and prompts insulin release when blood sugar is high. This is the foundation every drug in the field builds on.
GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone released after eating. It stimulates insulin and appears to influence how fat tissue stores and processes energy. Its exact contribution to weight loss is still debated, which is a genuinely open scientific question rather than settled fact.
Glucagon raises blood sugar, which sounds like the wrong direction. Its value here is that it increases energy expenditure, meaning more calories burned at rest, and it promotes breakdown of fat stored in the liver.
Amylin is released by your pancreas alongside insulin. It slows stomach emptying and signals fullness through the brainstem, a separate route from GLP-1's action on the hypothalamus.
The two strategies
Note that these split into different kinds of help.
GLP-1, GIP and amylin all work primarily on intake. They make you eat less.
Glucagon works on expenditure. It makes you burn more.
That is why glucagon-containing drugs are interesting despite the counterintuitive choice. They address the other side of the energy equation, which nothing else in this class does.
How the generations compare
Single agonist: semaglutide. GLP-1 only. Averaged 14.9 percent body weight reduction over 68 weeks in STEP 1.
Dual agonist: tirzepatide. GLP-1 plus GIP. Averaged 20.9 percent at 15 mg over 72 weeks in SURMOUNT-1, published in the New England Journal of Medicine.
Dual agonist: survodutide and mazdutide. GLP-1 plus glucagon. Survodutide produced 16.6 percent at 76 weeks in phase 3.
Combination: CagriSema. GLP-1 plus amylin, a different hormone system rather than another incretin. Around 20.4 percent in phase 3.
Triple agonist: retatrutide. GLP-1 plus GIP plus glucagon. Averaged 24.2 percent at 12 mg over 48 weeks in its phase 2 trial, published in the New England Journal of Medicine.
Notice that the two GLP-1 plus glucagon drugs did not outperform GLP-1 plus GIP. The pairing matters, not just the count.
Why the numbers are not directly comparable
This is the caveat most coverage skips.
Every figure above comes from a separate trial. Different participants, different starting weights, different durations, different years, different placebo responses.
Retatrutide's 24.2 percent also comes from phase 2, a smaller and shorter study than the phase 3 trials that produced the other numbers. Effects frequently shrink when tested in larger, more diverse populations.
The ordering is probably right. The precise gaps are not established. Only direct head-to-head trials settle that, and few exist.
The limits of stacking
Adding receptors is not free, and the field is approaching several constraints.
Side effects scale too. Every one of these drugs slows stomach emptying, so nausea, vomiting, diarrhoea and constipation increase alongside effectiveness. There is no version of this that delivers large results with no digestive cost.
Balance gets harder. Glucagon raises blood sugar while GLP-1 lowers it. The ratio has to be precisely tuned. More receptors means more interactions to balance, and more ways to get it wrong.
Muscle loss becomes a real concern. Losing 24 percent of body weight rapidly means losing lean tissue as well as fat. The next genuine problem in this field is not producing more weight loss. It is producing better quality weight loss, preserving muscle while removing fat.
Diminishing returns. The jump from one receptor to two added about six percentage points. Two to three added about three. The curve is flattening.
Where the field goes next
The direction is shifting away from simply stacking more receptors.
Combining with muscle-preserving agents is an active area, aiming to make the weight lost predominantly fat. Oral delivery is advancing, with orforglipron approved in April 2026 as a small-molecule tablet requiring no food restrictions. And targeting entirely separate hormone systems, as CagriSema does with amylin, may prove more productive than adding a fourth incretin receptor.
What any of this means in Pakistan
Very little, practically, and that is worth saying plainly.
None of the drugs discussed here is registered in Pakistan. Not semaglutide, approved in major markets since 2017. Not tirzepatide. Certainly not the unapproved ones.
Following this science is genuinely interesting and tells you where treatment is heading. It does not describe options available to you this month.
What is available works on the foundation receptor. GLP-1 pathway support delivered as drops targets the same pathway every drug above builds on, absorbed under the tongue rather than injected. METASLIM™ is a physician-reviewed supplement rather than a pharmaceutical agonist, single, dual or triple, so none of the trial figures here apply to it and nobody should present them as though they do. Its relevance is that it is obtainable here with physician review attached.
For the mechanism in plain terms, see the mechanism behind GLP-1 support. The complete GLP-1 medication list covers every approved drug, and retatrutide covers the triple agonist in detail.
The summary
More receptors have meant more weight loss, from roughly 15 percent with one to 24 percent with three.
GLP-1, GIP and amylin reduce intake. Glucagon increases expenditure. Which receptors you combine matters as much as how many.
The figures come from separate trials and should be read as an approximate ordering, not a precise league table.
Stacking is reaching its limits. Side effects scale with effect, balance becomes harder, and muscle preservation is becoming the more important problem than raw weight loss.
See the current program price for what is available in Pakistan today.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.